AbbVie launches two new oral treatments for hepatitis C

Exviera (dasabuvir) and Viekirax (ombitasvir/paritaprevir/ritonavir) are both indicated for the treatment of chronic hepatitis C infection.

by
Using dasabuvir and ombitasvir/paritaprevir/ritonavir together combines three direct-acting antivirals with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral life cycle | SCIENCE PHOTO
Using dasabuvir and ombitasvir/paritaprevir/ritonavir together combines three direct-acting antivirals with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral life cycle | SCIENCE PHOTO

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package